From left: Myosana CEO Matthew Lumley, with co-founders Stanley Froehner and Nick Whitehead. (Myosana and UW Photos) The news: Myosana Therapeutics, a Seattle startup developing gene therapy ...
Spinal muscular atrophy affects all the body’s muscles. For a long time, it was considered a disease caused solely by the loss of nerve cells in the spinal cord. Now, a research team at Leipzig ...
TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases ...
News Medical on MSN
Study uncovers cerebellar involvement and social impairment
Building on these findings, researchers at Leipzig University's Carl Ludwig Institute of Physiology have now investigated whether additional regions of the nervous system are involved in the ...
The contribution of selected physical development and muscular strength measures to general motor performance capacity was investigated in 55 seven to twelve year old boys. The physical development ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing orally bioavailable, small molecule therapies for musculoskeletal diseases, today ...
Dystroglycan, a muscle cell receptor whose dysfunction causes muscular dystrophy, actually has a critical role in brain development, researchers have discovered. Researchers at Stony Brook University ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback